BESREMi is a preferred, FDA-approved option for both symptomatic low- and high-risk polycythemia vera patients. In the polycythemia vera space, BESREMi faces competition from drugs like ruxolitinib, a ...
The "Intermediate AMD - Epidemiology Forecast - 2034" report has been added tAndMarkets.com's offering.The report delivers an in-depth understanding of Intermediate AMD, historical and forecasted ...
The "Asthma - Epidemiology Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. The report delivers an in-depth understanding of the asthma, historical and forecasted ...
The "Myopic Macular Degeneration (MMD) - Epidemiology Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.The report delivers an in-depth understanding of Myopic Macular ...
The "Myelofibrosis (MF) - Market Insight, Epidemiology, and Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. The report delivers an in-depth understanding of the ...
The report delivers an in-depth understanding of the asthma, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom ...
The report delivers an in-depth understanding of ocular melanoma, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom ...
The report delivers an in-depth understanding of Intermediate AMD, historical and forecasted epidemiology of Intermediate AMD in the United States, EU4 (Germany, France, Italy, and Spain ...
DelveInsight's “Menopause Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding ...
The overall market of herpes simplex is expected to boost with the expected launch of emerging therapy, increased awareness, and extensive research in the forecast period (2025-2034). LAS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results